A Phase 3 interventional study of rituximab in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Completed at 41 sites in 2 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2017-08-15.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 63 studies testing rituximab in Arthritis, Rheumatoid — 5 open to participants now, 6 under way, 1 of them phase 3. Rituximab · Arthritis, Rheumatoid.
Among the 63 studies testing rituximab in Arthritis, Rheumatoid, this one is the 37th largest by enrollment, is one of 11 that started in 2006, is one of 27 in phase 3, and was the 30th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →5 of the 63 studies testing rituximab in Arthritis, Rheumatoid are open now, in 4 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
University Hospital, Strasbourg, France · Sites in France
Ages 18+
Universitaire Ziekenhuizen KU Leuven · Sites in Belgium
Ages 18+
University of Nebraska · Sites in United States
Ages 19+
Chinese SLE Treatment And Research Group · Sites in China
Ages 18–80
By country, each count listing its studies:
Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
63 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 13 · Phase 3 27 · Phase 4 14
First in 2001; this study’s year is marked. 11 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 120 is above the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 159 across the 63 interventional studies. Of the 57 that completed or were terminated, 37 (65%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 63 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche: 2 open now, 2 under way, none of them phase 3. Of 214 finished, 139 (65%) have results posted.
Among the 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche, this one is the 74th largest by enrollment of the 141 interventional ones that give a count, is one of 13 that started in 2006, is one of 85 in phase 3, and was the 98th registered.
Hoffmann-La Roche’s Arthritis, Rheumatoid studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 63 studies testing rituximab in Arthritis, Rheumatoid, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Hoffmann-La Roche’s 219 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate the safety and effectiveness of MabThera (rituximab) in patients with active rheumatoid arthritis who are receiving methotrexate, and who have a previous or current inadequate response to one prior anti-TNF therapy. All patients will receive MabThera 1000 mg as an intravenous infusion on days 1 and 15. After the initial study phase of 24 weeks, eligible patients may receive one re-treatment with MabThera. The anticipated time on study treatment is 48 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: rituximab
1000 mg intravenously on Days 1 and 15
Percentage of Participants With Adverse Events During the Initial Treatment Period - Overall Summary
Percentage of participants who reported an AE or serious AE (SAE), a drug-related AE, who had an acute infusion reaction, an AE leading to study drug discontinuation, with an infection or serious infection, or who died.
Time frame: Days 1, 2, 15, and 16 and Week 48 of Initial treatment period
Percentage of Participants With Adverse Events During the Re-Treatment Period - Overall Summary
Percentage of participants who reported an AE or SAE, a drug-related AE, who had an acute infusion reaction, an AE leading to study drug discontinuation, with an infection or serious infection, or who died.
Time frame: Days 1, 2, 15, and 16 and Week 48 of Re-treatment period
Percentage of Participants Meeting American College of Rheumatology (ACR) Response Criteria During the Initial Treatment Period
ACR20/50/70, defined as ≥20 percent (%), 50%, or 70% improvement, respectively, compared to baseline in tender joint count (TJC) and swollen joint count (SJC), and 20%/50%/70% improvement in at least 3 of 5 additional ACR core set variables: Patient Assessment of Pain; Patient's Global Assessment of Disease Activity; Physician's Global Assessment of Disease Activity; Health Assessment Questionnaire - Disability Index (HAQ-DI); and an acute phase reactant (erythrocyte sedimentation rate \[ESR\] or C-Reactive Protein \[CRP\]). If CRP was missing or not done, then ESR was used.
Time frame: Weeks 4, 12, 24, 36, and 48 of Initial treatment period
Percentage of Participants With Complete Clinical Response Per ACR Criteria During the Initial Treatment Period
Complete clinical response was defined as having an ACR70 for at least 13 weeks.
Time frame: Weeks 4, 12, 24, 36, and 48 of Initial treatment period
Percentage of Participants Meeting ACR Response Criteria During the Re-treatment Period
ACR20/50/70, defined as ≥20%, 50%, or 70% improvement, respectively, compared to baseline in TJC and SJC, and 20%/50%/70% improvement in at least 3 of 5 additional ACR core set variables: Patient Assessment of Pain; Patient's Global Assessment of Disease Activity; Physician's Global Assessment of Disease Activity; HAQ-DI; and an acute phase reactant (ESR or CRP). If CRP was missing or not done, then ESR was used.
Time frame: Weeks 12 and 24 of Re-treatment period
Percentage of Participants With Complete Clinical Response Per ACR Criteria During the Re-Treatment Period
Complete clinical response was defined as having an ACR70 for at least 13 weeks.
Time frame: Weeks 12 and 24 of Re-treatment period
Percentage of Participants Meeting European League Against Rheumatism (EULAR) Response Criteria During the Initial Treatment Period
The EULAR response criteria were based on the assessment of disease activity using the DAS28. The EULAR response criteria included not only change in disease activity but current disease activity. To be classified as responders, participants had to have a significant change in DAS28 and a low current disease activity. There were 4 categories of EULAR response rates: good, moderate, good/moderate, and none. The DAS28 scoring used 4 core components: SJC, TJC, Patient's Global Assessment of Disease Activity, and ESR. The DAS28 has a continuous scale ranging from 0 to 9.4. The level of disease activity was interpreted as low (DAS28 score less than or equal to \[≤\]3.2), moderate (DAS28 score greater than \[\>\]3.2 but ≤5.1), or high (DAS28 score \>5.1). A DAS28 score \<2.6 corresponded to a state of remission according to American Rheumatism Association criteria.
Time frame: Weeks 4, 12, 24, 36, and 48 of Initial treatment period
Percentage of Participants Meeting EULAR Response Criteria During the Re-Treatment Period
The EULAR response criteria were based on the assessment of disease activity using the DAS28. The EULAR response criteria included not only change in disease activity but current disease activity. To be classified as responders, participants had to have a significant change in DAS28 and a low current disease activity. There were 4 categories of EULAR response rates: good, moderate, good/moderate, and none. The DAS28 scoring used 4 core components: SJC, TJC, Patient's Global Assessment of Disease Activity, and ESR. The DAS28 has a continuous scale ranging from 0 to 9.4. The level of disease activity was interpreted as low (DAS28 score ≤3.2), moderate (DAS28 score \>3.2 but ≤5.1), or high (DAS28 score \>5.1). A DAS28 score \<2.6 corresponded to a state of remission according to American Rheumatism Association criteria.
Time frame: Weeks 12 and 24 of Re-treatment period
Change From Baseline in DAS28 During the Initial Treatment Period
The DAS28 scoring used 4 core components: SJC, TJC, Patient's Global Assessment of Disease Activity, and ESR. The DAS28 has a continuous scale ranging from 0 to 9.4. The level of disease activity was interpreted as low (DAS28 score ≤3.2), moderate (DAS28 score \>3.2 but ≤5.1), or high (DAS28 score \>5.1). A DAS28 score \<2.6 corresponded to a state of remission according to American Rheumatism Association criteria. A change of 1.2 units in DAS28 in an individual participant was considered a significant change.
Time frame: Weeks 4, 12, 24, 36, and 48 of Initial treatment period
Change From Baseline in DAS28 During the Re-Treatment Period
The DAS28 scoring used 4 core components: SJC, TJC, Patient Global Assessment of Disease Activity, and ESR. The DAS28 has a continuous scale ranging from 0 to 9.4. The level of disease activity was interpreted as low (DAS28 score ≤3.2), moderate (DAS28 score \>3.2 but ≤5.1), or high (DAS28 score \>5.1). A DAS28 score \<2.6 corresponded to a state of remission according to American Rheumatism Association criteria. A change of 1.2 units in DAS28 in an individual participant was considered a significant change.
Time frame: Weeks 12 and 24 of Re-treatment period
Change From Baseline in SJC During the Initial Treatment Period
Joints assessed for swelling consisted of shoulders, elbows, wrists, interphalangeal (digit 1), distal interphalangeal joints (digits 2-5), proximal interphalangeal joints (digits 2-5), metacarpophalangeal joints (digits 1-5), and knees.
Time frame: Weeks 4, 12, 24, 36, and 48 of Initial treatment period
Change From Baseline in SJC During the Re-Treatment Period
Joints assessed for swelling consisted of shoulders, elbows, wrists, interphalangeal (digit 1), distal interphalangeal joints (digits 2-5), proximal interphalangeal joints (digits 2-5), metacarpophalangeal joints (digits 1-5), and knees.
Time frame: Weeks 12 and 24 of Re-treatment period
Change From Baseline in TJC During the Initial Treatment Period
Joints assessed for swelling consisted of shoulders, elbows, wrists, interphalangeal (digit 1), distal interphalangeal joints (digits 2-5), proximal interphalangeal joints (digits 2-5), metacarpophalangeal joints (digits 1-5), and knees.
Time frame: Weeks 4, 12, 24, 36, and 48 of Initial treatment period
Change From Baseline in TJC During the Re-Treatment Period
Joints assessed for swelling consisted of shoulders, elbows, wrists, interphalangeal (digit 1), distal interphalangeal joints (digits 2-5), proximal interphalangeal joints (digits 2-5), metacarpophalangeal joints (digits 1-5), and knees.
Time frame: Weeks 12 and 24 of Re-treatment period
Change From Baseline in Physician's Global Assessment of Disease Activity During the Initial Treatment Period
Physician Global Assessment of Disease Activity was measured using a 100-mm visual analog scale (VAS) where the extreme left end of the line was 0 = no disease activity and the extreme right end of the line was 100 = maximum disease activity. The physician marked the line and the distance from the left edge was measured in mm.
Time frame: Weeks 4, 12, 24, 36, and 48 of Initial treatment period
Change From Baseline in Physician's Global Assessment of Disease Activity During the Re-Treatment Period
Physician Global Assessment of Disease Activity was measured using a 100-mm VAS where the extreme left end of the line was 0 = no disease activity and the extreme right end of the line was 100 = maximum disease activity. The physician marked the line and the distance from the left edge was measured in mm.
Time frame: Weeks 12 and 24 of Re-treatment period
Change From Baseline in Patient Global Assessment of Disease Activity Score During the Initial Treatment Period
Patient Global Assessment of Disease Activity was measured using a 100-mm VAS where the extreme left end of the line was 0 = no disease activity and the extreme right end of the line was 100 = maximum disease activity. The participant was asked to marked the line and the distance from the left edge was measured in mm.
Time frame: Weeks 4, 12, 24, 36, and 48 of Initial treatment period
Change From Baseline in Patient Global Assessment of Disease Activity During the Re-Treatment Period
Patient Global Assessment of Disease Activity was measured using a 100-mm VAS where the extreme left end of the line was 0 = no disease activity and the extreme right end of the line was 100 = maximum disease activity. The participant was asked to marked the line and the distance from the left edge was measured in mm.
Time frame: Weeks 12 and 24 of Re-treatment period and Week 4 after last maintenance
Change From Baseline in Patient Global Assessment of Pain During the Initial Treatment Period
Patient Global Assessment of Pain was measured using a 100-mm VAS where the extreme left end of the line was 0 = no pain and the extreme right end of the line was 100 = unbearable pain. The participant was asked to mark the line and the distance from the left edge was measured in mm.
Time frame: Weeks 4, 12, 24, 36, and 48 of Initial treatment period
Change From Baseline in Patient Global Assessment of Pain During the Re-Treatment Period
Patient Global Assessment of Pain was measured using a 100-mm VAS where the extreme left end of the line was 0 = no pain and the extreme right end of the line was 100 = unbearable pain. The participant was asked to mark the line and the distance from the left edge was measured in mm.
Time frame: Weeks 12 and 24 of Re-treatment period
Change From Baseline HAQ-DI Score During the Initial Treatment Period
HAQ-DI: 20 questions, 8 categories of functioning: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and common usual activities. Participants report amount of difficulty in performing 2-3 specific subcategory items. Difficulty score is from 0 to 3 (0 = without any difficulty; 1 = with some difficulty; 2 = with much difficulty; and 3 = unable to do). The highest component score in each of the 8 categories determined the score for that category, unless aids, devices, and/or help from another person were required which = a score of 2 (unless already 2 or 3). The 8 category scores were averaged into overall HAQ-DI score ranging from 0 to 3 (0 to 1 = mild to moderate difficulty; 1 to 2 = moderate to severe disability; and 2 to 3 = severe to very severe disability). HAQ-DI not computed if \> 2 categories were missing.
Time frame: Weeks 4, 12, 24, 36, and 48 of Initial treatment period
Change From Baseline HAQ-DI Score During the Re-Treatment Period
HAQ-DI: 20 questions, 8 categories of functioning: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and common usual activities. Participants report amount of difficulty in performing 2-3 specific subcategory items. Difficulty score is from 0 to 3 (0 = without any difficulty; 1 = with some difficulty; 2 = with much difficulty; and 3 = unable to do). The highest component score in each of the 8 categories determines the score for that category, unless aids, devices, and/or help from another person were required which = a score of 2 (unless already 2 or 3). The 8 category scores were averaged into overall HAQ-DI score ranging from 0 to 3 (0 to 1 = mild to moderate difficulty; 1 to 2 = moderate to severe disability; and 2 to 3 = severe to very severe disability). HAQ-DI not computed if \>2 categories were missing.
Time frame: Weeks 12 and 24 of Re-treatment period
Change From Baseline in ESR During the Initial Treatment Period
ESR was measured in mm/hour and was used to determine the acute phase response. Lower ESR values indicate reduction in disease activity; normal reference range: 0-20 mm/hr.
Time frame: Weeks 4, 12, 24, 36, and 48 of Initial treatment period
Change From Baseline in ESR During the Re-Treatment Period
ESR was measured in mm/hour and was used to determine the acute phase response. Lower ESR values indicate reduction in disease activity; normal reference range: 0-20 mm/hr.
Time frame: Weeks 12 and 24 of Re-treatment period
Change From Baseline in CRP During the Initial Treatment Period
CRP levels were measured in milligrams/liter (mg/L) and were used to determine the acute phase response. A reduction in CRP levels is considered an improvement; normal reference range ≤10 mg/L.
Time frame: Weeks 4, 12, 24, 36, and 48 of Initial treatment period
Change From Baseline CRP During the Re-Treatment Period
CRP levels were measured in mg/L and were used to determine the acute phase response. A reduction in CRP levels is considered an improvement; normal reference range ≤10 mg/L.
Time frame: Weeks 12 and 24 of Re-treatment period
Percentage of Participants With Disease Remission According to DAS28 in the Initial Treatment Period
The DAS28 scoring used 4 core components: SJC, TJC, Patient's Global Assessment of Disease Activity, and ESR. The DAS28 has a continuous scale ranging from 0 to 9.4. The level of disease activity was interpreted as low (DAS28 score ≤3.2), moderate (DAS28 score \>3.2 but ≤5.1), or high (DAS28 score \>5.1). A DAS28 score ≤2.6 corresponded to a state of remission according to American Rheumatism Association criteria.
Time frame: Weeks 4, 12, 24, 36, and 48 of Initial treatment period
Percentage of Participants With Disease Remission According to DAS28 in the Re-Treatment Period
The DAS28 scoring used 4 core components: SJC, TJC, Patient's Global Assessment of Disease Activity, and ESR. The DAS28 has a continuous scale ranging from 0 to 9.4. The level of disease activity was interpreted as low (DAS28 score ≤3.2), moderate (DAS28 score \>3.2 but ≤5.1), or high (DAS28 score \>5.1). A DAS28 score ≤2.6 corresponded to a state of remission according to American Rheumatism Association criteria.
Time frame: Weeks 12 and 24 of Re-treatment period
Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Total Score During the Initial Treatment Period
Participant fatigue was evaluated using the FACIT-F scale, a 13-item questionnaire in which the participants were requested to score each item on a 5-point scale. The FACIT-F scores ranged from 0 to 52, with higher scores representing less fatigue. Score changes of 4 points or more were considered clinically meaningful. The total score was a summation of all 13 items, where 2 of the positive items (I have energy; I am able to do my usual activities) were reversed for scoring.
Time frame: Weeks 4, 12, 24, 36, and 48 of Initial treatment period
Change From Baseline in FACIT-F Total Score During the Re-Treatment Period
Participant fatigue was evaluated using the FACIT-F scale, a 13-item questionnaire in which the participants were requested to score each item on a 5-point scale. The FACIT-F scores ranged from 0 to 52, with higher scores representing less fatigue. Score changes of 4 points or more were considered clinically meaningful. The total score was a summation of all 13 items, where 2 of the positive items (I have energy; I am able to do my usual activities) were reversed for scoring.
Time frame: Weeks 12 and 24 of Re-treatment period
| Milestone | Rituximab + Methotrexate (MTX) |
|---|---|
| Started | 120 |
| Completed | 112 |
| Not completed | 8 |
| Withdrew: Adverse event | 1 |
| Withdrew: Lack of efficacy | 5 |
| Withdrew: Protocol violation | 1 |
| Withdrew: Withdrawal by subject | 1 |
| Milestone | Rituximab + Methotrexate (MTX) |
|---|---|
| Started | 77 |
| Completed | 71 |
| Not completed | 6 |
| Withdrew: Adverse event | 2 |
| Withdrew: Lack of efficacy | 3 |
| Withdrew: Withdrawal by subject | 1 |
Percentage of participants who reported an AE or serious AE (SAE), a drug-related AE, who had an acute infusion reaction, an AE leading to study drug discontinuation, with an infection or serious infection, or who died.
| percentage of participants | Initial Treatment Period: Rituximab + MTX |
|---|---|
| With an AE | 85.0 |
| With a drug-related AE | 41.7 |
| With an acute infusion reaction | 20.8 |
| With AE leading to study drug discontinuation | 4.2 |
| With an SAE | 10.0 |
| With infections | 47.5 |
| With a serious infections | 2.5 |
| Who died | 0 |
Percentage of participants who reported an AE or SAE, a drug-related AE, who had an acute infusion reaction, an AE leading to study drug discontinuation, with an infection or serious infection, or who died.
| percentage of participants | Re-Treatment Period: Rituximab + MTX |
|---|---|
| With an AE | 68.8 |
| With a drug-related AE | 27.3 |
| With an acute infusion reaction | 13.0 |
| With AE leading to study drug discontinuation | 1.3 |
| With an SAE | 9.1 |
| With infections | 27.3 |
| With a serious infections | 2.6 |
| Who died | 0 |
ACR20/50/70, defined as ≥20 percent (%), 50%, or 70% improvement, respectively, compared to baseline in tender joint count (TJC) and swollen joint count (SJC), and 20%/50%/70% improvement in at least 3 of 5 additional ACR core set variables: Patient Assessment of Pain; Patient's Global Assessment of Disease Activity; Physician's Global Assessment of Disease Activity; Health Assessment Questionnaire - Disability Index (HAQ-DI); and an acute phase reactant (erythrocyte sedimentation rate \[ESR\] or C-Reactive Protein \[CRP\]). If CRP was missing or not done, then ESR was used.
| percentage of participants | Initial Treatment Period: Rituximab + MTX |
|---|---|
| ACR20, Week 4 | 31.7 |
| ACR20, Week 12 | 50.0 |
| ACR20, Week 24 | 54.2 |
| ACR20, Week 36 | 25.0 |
| ACR20, Week 48 | 15.8 |
| ACR50, Week 4 | 5.8 |
| ACR50, Week 12 | 22.5 |
| ACR50, Week 24 | 25.0 |
| ACR50, Week 36 | 11.7 |
| ACR50, Week 48 | 9.2 |
| ACR70, Week 4 | 0 |
| ACR70, Week 12 | 4.2 |
| ACR70, Week 24 | 5.8 |
| ACR70, Week 36 | 5.8 |
| ACR70, Week 48 | 4.2 |
Complete clinical response was defined as having an ACR70 for at least 13 weeks.
| percentage of participants | Initial Treatment Period: Rituximab + MTX |
|---|---|
| Percentage of Participants With Complete Clinical Response Per ACR Criteria During the Initial Treatment Period | 4.2 |
ACR20/50/70, defined as ≥20%, 50%, or 70% improvement, respectively, compared to baseline in TJC and SJC, and 20%/50%/70% improvement in at least 3 of 5 additional ACR core set variables: Patient Assessment of Pain; Patient's Global Assessment of Disease Activity; Physician's Global Assessment of Disease Activity; HAQ-DI; and an acute phase reactant (ESR or CRP). If CRP was missing or not done, then ESR was used.
| percentage of participants | Re-Treatment Period: Rituximab + MTX |
|---|---|
| ACR20, Week 12 | 54.5 |
| ACR20, Week 24 | 58.4 |
| ACR50, Week 12 | 26.0 |
| ACR50, Week 24 | 28.6 |
| ACR70, Week 12 | 6.5 |
| ACR70, Week 24 | 9.1 |
Complete clinical response was defined as having an ACR70 for at least 13 weeks.
| percentage of participants | Re-Treatment Period: Rituximab + MTX |
|---|---|
| Percentage of Participants With Complete Clinical Response Per ACR Criteria During the Re-Treatment Period | 1.3 |
The EULAR response criteria were based on the assessment of disease activity using the DAS28. The EULAR response criteria included not only change in disease activity but current disease activity. To be classified as responders, participants had to have a significant change in DAS28 and a low current disease activity. There were 4 categories of EULAR response rates: good, moderate, good/moderate, and none. The DAS28 scoring used 4 core components: SJC, TJC, Patient's Global Assessment of Disease Activity, and ESR. The DAS28 has a continuous scale ranging from 0 to 9.4. The level of disease activity was interpreted as low (DAS28 score less than or equal to \[≤\]3.2), moderate (DAS28 score greater than \[\>\]3.2 but ≤5.1), or high (DAS28 score \>5.1). A DAS28 score \<2.6 corresponded to a state of remission according to American Rheumatism Association criteria.
| percentage of participants | Initial Treatment Period: Rituximab + MTX |
|---|---|
| Week 4: Good | 4.2 |
| Week 4: Moderate | 47.5 |
| Week 4: Good/Moderate | 51.7 |
| Week 4: None | 46.7 |
| Week 12: Good | 9.2 |
| Week 12: Moderate | 55.0 |
| Week 12: Good/Moderate | 64.2 |
| Week 12: None | 33.3 |
| Week 24: Good | 17.5 |
| Week 24: Moderate | 50.0 |
| Week 24: Good/Moderate | 67.5 |
| Week 24: None | 26.7 |
| Week 36: Good | 10.8 |
| Week 36: Moderate | 24.2 |
| Week 36: Good/Moderate | 35.0 |
| Week 36: None | 23.3 |
| Week 48: Good | 8.3 |
| Week 48: Moderate | 10.8 |
| Week 48: Good/Moderate | 19.2 |
| Week 48: None | 10.0 |
The EULAR response criteria were based on the assessment of disease activity using the DAS28. The EULAR response criteria included not only change in disease activity but current disease activity. To be classified as responders, participants had to have a significant change in DAS28 and a low current disease activity. There were 4 categories of EULAR response rates: good, moderate, good/moderate, and none. The DAS28 scoring used 4 core components: SJC, TJC, Patient's Global Assessment of Disease Activity, and ESR. The DAS28 has a continuous scale ranging from 0 to 9.4. The level of disease activity was interpreted as low (DAS28 score ≤3.2), moderate (DAS28 score \>3.2 but ≤5.1), or high (DAS28 score \>5.1). A DAS28 score \<2.6 corresponded to a state of remission according to American Rheumatism Association criteria.
| percentage of participants | Re-Treatment Period: Rituximab + MTX |
|---|---|
| Week 12: Good | 20.8 |
| Week 12: Moderate | 53.2 |
| Week 12: Good/Moderate | 74.0 |
| Week 12: None | 22.1 |
| Week 24: Good | 19.5 |
| Week 24: Moderate | 48.1 |
| Week 24: Good/Moderate | 67.5 |
| Week 24: None | 26.0 |
The DAS28 scoring used 4 core components: SJC, TJC, Patient's Global Assessment of Disease Activity, and ESR. The DAS28 has a continuous scale ranging from 0 to 9.4. The level of disease activity was interpreted as low (DAS28 score ≤3.2), moderate (DAS28 score \>3.2 but ≤5.1), or high (DAS28 score \>5.1). A DAS28 score \<2.6 corresponded to a state of remission according to American Rheumatism Association criteria. A change of 1.2 units in DAS28 in an individual participant was considered a significant change.
| scores on a scale | Initial Treatment Period: Rituximab + MTX |
|---|---|
| Baseline (n=117) | 6.4 ± 1.1 |
| Change at Week 4 (n=112) | -1.1 ± 0.8 |
| Change at Week 12 (n=108) | -1.7 ± 1.2 |
| Change at Week 24 (n=105) | -2.0 ± 1.2 |
| Change at Week 36 (n=66) | -1.7 ± 1.7 |
| Change at Week 48 (n=33) | -2.1 ± 1.6 |
The DAS28 scoring used 4 core components: SJC, TJC, Patient Global Assessment of Disease Activity, and ESR. The DAS28 has a continuous scale ranging from 0 to 9.4. The level of disease activity was interpreted as low (DAS28 score ≤3.2), moderate (DAS28 score \>3.2 but ≤5.1), or high (DAS28 score \>5.1). A DAS28 score \<2.6 corresponded to a state of remission according to American Rheumatism Association criteria. A change of 1.2 units in DAS28 in an individual participant was considered a significant change.
| scores on a scale | Re-Treatment Period: Rituximab + MTX |
|---|---|
| Baseline (n=117) | 6.4 ± 1.1 |
| Change at Week 12 (n=70) | -2.3 ± 1.3 |
| Change at Week 24 (n=65) | -2.2 ± 1.4 |
Joints assessed for swelling consisted of shoulders, elbows, wrists, interphalangeal (digit 1), distal interphalangeal joints (digits 2-5), proximal interphalangeal joints (digits 2-5), metacarpophalangeal joints (digits 1-5), and knees.
| swollen joints | Initial Treatment Period: Rituximab + MTX |
|---|---|
| Baseline (n=117) | 13.7 ± 5.33 |
| Change at Week 4 (n=115) | -3.6 ± 4.45 |
| Change at Week 12 (n=113) | -5.7 ± 4.97 |
| Change at Week 24 (n=106) | -7.1 ± 5.66 |
| Change at Week 36 (n=67) | -5.6 ± 6.50 |
| Change at Week 48 (n=33) | -7.7 ± 5.56 |
Joints assessed for swelling consisted of shoulders, elbows, wrists, interphalangeal (digit 1), distal interphalangeal joints (digits 2-5), proximal interphalangeal joints (digits 2-5), metacarpophalangeal joints (digits 1-5), and knees.
| swollen joints | Initial Treatment Period: Rituximab + MTX |
|---|---|
| Baseline (n=117) | 13.7 ± 5.33 |
| Change at Week 12 (n=71) | -7.6 ± 6.07 |
| Change at Week 24 (n=69) | -7.7 ± 5.43 |
Joints assessed for swelling consisted of shoulders, elbows, wrists, interphalangeal (digit 1), distal interphalangeal joints (digits 2-5), proximal interphalangeal joints (digits 2-5), metacarpophalangeal joints (digits 1-5), and knees.
| tender joints | Initial Treatment Period: Rituximab + MTX |
|---|---|
| Baseline (n=117) | 16.1 ± 6.62 |
| Change at Week 4 (n=115) | -6.3 ± 5.95 |
| Change at Week 12 (n=113) | -7.8 ± 6.68 |
| Change at Week 24 (n=106) | -9.0 ± 6.42 |
| Change at Week 36 (n=67) | -7.4 ± 8.35 |
| Change at Week 48 (n=33) | -7.8 ± 8.31 |
Joints assessed for swelling consisted of shoulders, elbows, wrists, interphalangeal (digit 1), distal interphalangeal joints (digits 2-5), proximal interphalangeal joints (digits 2-5), metacarpophalangeal joints (digits 1-5), and knees.
| tender joints | Re-Treatment Period: Rituximab + MTX |
|---|---|
| Baseline (n=117) | 16.1 ± 6.62 |
| Change at Week 12 (n=71) | -9.4 ± 7.54 |
| Change at Week 24 (n=69) | -9.7 ± 6.92 |
Physician Global Assessment of Disease Activity was measured using a 100-mm visual analog scale (VAS) where the extreme left end of the line was 0 = no disease activity and the extreme right end of the line was 100 = maximum disease activity. The physician marked the line and the distance from the left edge was measured in mm.
| mm | Initial Treatment Period: Rituximab + MTX |
|---|---|
| Baseline (n=120) | 68.6 ± 17.34 |
| Change at Week 4 (n=117) | -22.0 ± 21.67 |
| Change at Week 12 (n=116) | -31.4 ± 24.28 |
| Change at Week 24 (n=109) | -35.1 ± 24.45 |
| Change at Week 36 (n=68) | -28.6 ± 28.68 |
| Change at Week 48 (n=34) | -35.9 ± 25.18 |
Physician Global Assessment of Disease Activity was measured using a 100-mm VAS where the extreme left end of the line was 0 = no disease activity and the extreme right end of the line was 100 = maximum disease activity. The physician marked the line and the distance from the left edge was measured in mm.
| mm | Re-Treatment Period: Rituximab + MTX |
|---|---|
| Baseline (n=120) | 68.6 ± 17.34 |
| Change at Week 12 (n=73) | -35.5 ± 25.95 |
| Change at Week 24 (n=69) | -41.5 ± 24.43 |
Patient Global Assessment of Disease Activity was measured using a 100-mm VAS where the extreme left end of the line was 0 = no disease activity and the extreme right end of the line was 100 = maximum disease activity. The participant was asked to marked the line and the distance from the left edge was measured in mm.
| mm | Initial Treatment Period: Rituximab + MTX |
|---|---|
| Baseline (n=120) | 67.5 ± 22.73 |
| Change at Week 4 (n=117) | -19.7 ± 21.50 |
| Change at Week 12 (n=116) | -26.3 ± 26.84 |
| Change at Week 24 (n=109) | -29.2 ± 25.72 |
| Change at Week 36 (n=68) | -23.8 ± 30.42 |
| Change at Week 48 (n=34) | -28.5 ± 22.92 |
Patient Global Assessment of Disease Activity was measured using a 100-mm VAS where the extreme left end of the line was 0 = no disease activity and the extreme right end of the line was 100 = maximum disease activity. The participant was asked to marked the line and the distance from the left edge was measured in mm.
| mm | Re-Treatment Period: Rituximab + MTX |
|---|---|
| Baseline (n=120) | 67.5 ± 22.73 |
| Change at Week 12 (n=72) | -32.6 ± 29.20 |
| Change at Week 24 (n=72) | -30.7 ± 28.70 |
Patient Global Assessment of Pain was measured using a 100-mm VAS where the extreme left end of the line was 0 = no pain and the extreme right end of the line was 100 = unbearable pain. The participant was asked to mark the line and the distance from the left edge was measured in mm.
| mm | Initial Treatment Period: Rituximab + MTX |
|---|---|
| Baseline (n=120) | 60.2 ± 22.85 |
| Change at Week 4 (n=117) | -17.5 ± 21.80 |
| Change at Week 12 (n=113) | -24.0 ± 25.31 |
| Change at Week 24 (n=108) | -25.7 ± 25.40 |
| Change at Week 36 (n=68) | -18.0 ± 29.18 |
| Change at Week 48 (n=33) | -22.6 ± 20.07 |
Patient Global Assessment of Pain was measured using a 100-mm VAS where the extreme left end of the line was 0 = no pain and the extreme right end of the line was 100 = unbearable pain. The participant was asked to mark the line and the distance from the left edge was measured in mm.
| mm | Re-Treatment Period: Rituximab + MTX |
|---|---|
| Baseline (n=120) | 60.2 ± 22.85 |
| Change at Week 12 (n=72) | -28.3 ± 28.02 |
| Change at Week 24 (n=72) | -26.6 ± 27.61 |
HAQ-DI: 20 questions, 8 categories of functioning: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and common usual activities. Participants report amount of difficulty in performing 2-3 specific subcategory items. Difficulty score is from 0 to 3 (0 = without any difficulty; 1 = with some difficulty; 2 = with much difficulty; and 3 = unable to do). The highest component score in each of the 8 categories determined the score for that category, unless aids, devices, and/or help from another person were required which = a score of 2 (unless already 2 or 3). The 8 category scores were averaged into overall HAQ-DI score ranging from 0 to 3 (0 to 1 = mild to moderate difficulty; 1 to 2 = moderate to severe disability; and 2 to 3 = severe to very severe disability). HAQ-DI not computed if \> 2 categories were missing.
| scores on a scale | Initial Treatment Period: Rituximab + MTX |
|---|---|
| Baseline (n=120) | 1.7 ± 0.57 |
| Change at Week 4 (n=117) | -0.2 ± 0.36 |
| Change at Week 12 (n=116) | -0.3 ± 0.46 |
| Change at Week 24 (n=108) | -0.4 ± 0.48 |
| Change at Week 36 (n=68) | -0.3 ± 0.53 |
| Change at Week 48 (n=34) | -0.4 ± 0.56 |
HAQ-DI: 20 questions, 8 categories of functioning: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and common usual activities. Participants report amount of difficulty in performing 2-3 specific subcategory items. Difficulty score is from 0 to 3 (0 = without any difficulty; 1 = with some difficulty; 2 = with much difficulty; and 3 = unable to do). The highest component score in each of the 8 categories determines the score for that category, unless aids, devices, and/or help from another person were required which = a score of 2 (unless already 2 or 3). The 8 category scores were averaged into overall HAQ-DI score ranging from 0 to 3 (0 to 1 = mild to moderate difficulty; 1 to 2 = moderate to severe disability; and 2 to 3 = severe to very severe disability). HAQ-DI not computed if \>2 categories were missing.
| scores on a scale | Re-Treatment Period: Rituximab + MTX |
|---|---|
| Baseline (n=120) | 1.7 ± 0.57 |
| Change at Week 12 (n=73) | -0.5 ± 0.60 |
| Change at Week 24 (n=72) | -0.5 ± 0.62 |
ESR was measured in mm/hour and was used to determine the acute phase response. Lower ESR values indicate reduction in disease activity; normal reference range: 0-20 mm/hr.
| mm/hr | Initial Treatment Period: Rituximab + MTX |
|---|---|
| Baseline (n=120) | 37.0 ± 27.84 |
| Change at Week 4 (n=112) | -4.5 ± 13.57 |
| Change at Week 12 (n=112) | -11.3 ± 20.60 |
| Change at Week 24 (n=107) | -16.0 ± 20.36 |
| Change at Week 36 (n=68) | -9.2 ± 22.29 |
| Change at Week 48 (n=34) | -12.0 ± 17.93 |
ESR was measured in mm/hour and was used to determine the acute phase response. Lower ESR values indicate reduction in disease activity; normal reference range: 0-20 mm/hr.
| mm/hr | Re-Treatment Period: Rituximab + MTX |
|---|---|
| Baseline (n=120) | 37.0 ± 27.84 |
| Change at Week 12 (n=73) | -17.9 ± 22.07 |
| Change at Week 24 (n=67) | -18.7 ± 23.05 |
CRP levels were measured in milligrams/liter (mg/L) and were used to determine the acute phase response. A reduction in CRP levels is considered an improvement; normal reference range ≤10 mg/L.
| mg/L | Initial Treatment Period: Rituximab + MTX |
|---|---|
| Baseline (n=119) | 25.6 ± 28.87 |
| Change at Week 4 (n=110) | -7.9 ± 17.44 |
| Change at Week 12 (n=113) | -11.9 ± 31.97 |
| Change at Week 24 (n=108) | -16.1 ± 24.82 |
| Change at Week 36 (n=67) | -9.1 ± 25.74 |
| Change at Week 48 (n=34) | -7.6 ± 27.06 |
CRP levels were measured in mg/L and were used to determine the acute phase response. A reduction in CRP levels is considered an improvement; normal reference range ≤10 mg/L.
| mg/L | Re-Treatment Period: Rituximab + MTX |
|---|---|
| Baseline (n=119) | 25.6 ± 28.87 |
| Change at Week 12 (n=70) | -16.9 ± 27.15 |
| Change at Week 24 (n=67) | -15.3 ± 26.62 |
The DAS28 scoring used 4 core components: SJC, TJC, Patient's Global Assessment of Disease Activity, and ESR. The DAS28 has a continuous scale ranging from 0 to 9.4. The level of disease activity was interpreted as low (DAS28 score ≤3.2), moderate (DAS28 score \>3.2 but ≤5.1), or high (DAS28 score \>5.1). A DAS28 score ≤2.6 corresponded to a state of remission according to American Rheumatism Association criteria.
| percentage of participants | Initial Treatment Period: Rituximab + MTX |
|---|---|
| Week 4 | 0.8 |
| Week 12 | 5.0 |
| Week 24 | 5.8 |
| Week 36 | 5.8 |
| Week 48 | 5.8 |
The DAS28 scoring used 4 core components: SJC, TJC, Patient's Global Assessment of Disease Activity, and ESR. The DAS28 has a continuous scale ranging from 0 to 9.4. The level of disease activity was interpreted as low (DAS28 score ≤3.2), moderate (DAS28 score \>3.2 but ≤5.1), or high (DAS28 score \>5.1). A DAS28 score ≤2.6 corresponded to a state of remission according to American Rheumatism Association criteria.
| percentage of participants | Re-Treatment Period: Rituximab + MTX |
|---|---|
| Week 12 | 5.0 |
| Week 24 | 4.2 |
Participant fatigue was evaluated using the FACIT-F scale, a 13-item questionnaire in which the participants were requested to score each item on a 5-point scale. The FACIT-F scores ranged from 0 to 52, with higher scores representing less fatigue. Score changes of 4 points or more were considered clinically meaningful. The total score was a summation of all 13 items, where 2 of the positive items (I have energy; I am able to do my usual activities) were reversed for scoring.
| scores on a scale | Initial Treatment Period: Rituximab + MTX |
|---|---|
| Baseline (n=120) | 28.9 ± 10.22 |
| Change at Week 4 (n=116) | -5.4 ± 8.19 |
| Change at Week 12 (n=116) | -7.3 ± 10.38 |
| Change at Week 24 (n=108) | -9.1 ± 9.90 |
| Change at Week 36 (n=68) | -8.6 ± 11.71 |
| Change at Week 48 (n=34) | -10.9 ± 10.68 |
Participant fatigue was evaluated using the FACIT-F scale, a 13-item questionnaire in which the participants were requested to score each item on a 5-point scale. The FACIT-F scores ranged from 0 to 52, with higher scores representing less fatigue. Score changes of 4 points or more were considered clinically meaningful. The total score was a summation of all 13 items, where 2 of the positive items (I have energy; I am able to do my usual activities) were reversed for scoring.
| scores on a scale | Re-Treatment Period: Rituximab + MTX |
|---|---|
| Baseline (n=120) | 28.9 ± 10.22 |
| Change at Week 12 (n=73) | -8.3 ± 12.64 |
| Change at Week 24 (n=72) | -8.9 ± 11.72 |
Collected over Reporting period began after written informed consent was obtained and ended 48 weeks after therapy was initiated or 24 weeks after re-treatment had occurred.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Initial Treatment: Rituximab + MTX | — | 12/120 (10%) | 102/120 (85%) |
| Re-treatment: Rituximab + MTX | — | 7/77 (9.1%) | 53/77 (68.8%) |
| Event | Initial Treatment: Rituximab + MTX | Re-treatment: Rituximab + MTX |
|---|---|---|
| Hip fractureInjury, poisoning and procedural complications | 2/120 | 0/77 |
| Urinary tract infectionInfections and infestations | 1/120 | 1/77 |
| Breast cellulitisInfections and infestations | 0/120 | 1/77 |
| Ovarian epithelial cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/120 | 1/77 |
| Upper limb fractureInjury, poisoning and procedural complications | 0/120 | 1/77 |
| Large intestine perforationGastrointestinal disorders | 0/120 | 1/77 |
| HeadacheNervous system disorders | 0/120 | 1/77 |
| Vision blurredEye disorders | 0/120 | 1/77 |
| Pulmonary fibrosisRespiratory, thoracic and mediastinal disorders | 0/120 | 1/77 |
| LabyrinthitisInfections and infestations | 1/120 | 0/77 |
| Event | Initial Treatment: Rituximab + MTX | Re-treatment: Rituximab + MTX |
|---|---|---|
| Rheumatoid arthritisMusculoskeletal and connective tissue disorders | 20/120 | 5/77 |
| NauseaGastrointestinal disorders | 17/120 | 9/77 |
| HeadacheNervous system disorders | 14/120 | 6/77 |
| NasopharyngitisInfections and infestations | 13/120 | 8/77 |
| CoughRespiratory, thoracic and mediastinal disorders | 13/120 | 2/77 |
| FatigueGeneral disorders | 10/120 | 1/77 |
| Urinary tract infectionInfections and infestations | 9/120 | 3/77 |
| Back painMusculoskeletal and connective tissue disorders | 9/120 | 3/77 |
| DizzinessNervous system disorders | 9/120 | 3/77 |
| VomitingGastrointestinal disorders | 7/120 | 5/77 |
Intent-to-Treat (ITT) Population: all participants who recieved any amount of infused medication whether or not they completed any further assessment.
| Age, Continuous(years) | Rituximab + MTX |
|---|---|
| Mean | 55.6 ± 10.20 |
| Sex: Female, Male(Participants) | Rituximab + MTX |
|---|---|
| Female | 87 |
| Male | 33 |
Ran from Jul 2006 to primary completion in Mar 2009, 31 months.
Results were first posted in Aug 2014, 5 years 4 months after primary completion.
Of 116 industry-sponsored phase 3 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's 31 months is above that.
Counting every sponsor, half of 148 studies reached it within 26 months; a quarter within 17 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rituximab